Solid Tumor Clinical Trials in Jacksonville, Florida

9 studies are recruiting for solid tumor in Jacksonville, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

   The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected solid tumors expressing SSTRs.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Facility, Jacksonville, Florida

   Locations

   14 in total

   Run by

   RayzeBio, Inc.

   See if you can join NCT07165132 on ClinicalTrials.gov

2. Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

   This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic, Jacksonville, Florida

   Locations

   25 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT05245500 on ClinicalTrials.gov

3. FOG-001 in Locally Advanced or Metastatic Solid Tumors

   The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic, Jacksonville, Florida

   Locations

   33 in total

   Run by

   Parabilis Medicines, Inc.

   See if you can join NCT05919264 on ClinicalTrials.gov

4. Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

   This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alone, and in combination with nivolumab (doublet), nivolumab + …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Exelixis Clinical Site #78, Jacksonville, Florida

   Locations

   122 in total

   Run by

   Exelixis

   See if you can join NCT05176483 on ClinicalTrials.gov

5. A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

   Fibroblast activation protein (FAP) is a cell surface protein that is highly expressed on the surface of cancer-associated fibroblasts (CAFs) present in the tumor microenvironment of most epithelial cancers, whereas limited expression of FAP is observed in normal tissues. In some cancers of mesench…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic, Jacksonville, Florida

   Locations

   41 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT04939610 on ClinicalTrials.gov

6. An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

   The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and/or solid tumor indications or advanced malignancies. Additionally, participants previously enrolled in studies with pelabresib who received placebo or participants…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Mayo Clinic Jacksonville, Jacksonville, Florida

   Locations

   15 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06401356 on ClinicalTrials.gov

7. Ex Vivo Expansion (ACT-X)

   The purpose of this study is to understand how the body's immune cells respond to a new type of vaccine (neoantigen vaccine) designed to help the immune system recognize and fight cancer. To do this, the study team will collect a research specimen from participants to study their immune cells' reac…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Mayo Clinic in Florida, Jacksonville, Florida

   Run by

   Mayo Clinic

   See if you can join NCT07137312 on ClinicalTrials.gov

8. Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

   This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tum…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic Jacksonville, Jacksonville, Florida

   Locations

   15 in total

   Run by

   Tango Therapeutics, Inc.

   See if you can join NCT06810544 on ClinicalTrials.gov

9. A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors

   Part 1 of this study is an open-label, dose-escalation, and safety expansion study of an anti-LILRB2 / anti-PD-L1 bispecific antibody SPX- 303 in patients with solid tumors. Part 2 of this study is an indication-specific dose expansion study of SPX-303.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic Florida, Jacksonville, Florida

   Locations

   4 in total

   Run by

   SparX Biotech(Jiangsu) Co., Ltd.

   See if you can join NCT06259552 on ClinicalTrials.gov